Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DocCheck AGFRA:AJ91 +0.87%71 PB Ratio is 1.41 as of Jul. 22, 2026, which is 32% below its 10-year median of 2.06. GuruFocus rates FRA:AJ91 with a GF Score™ of 71/100 and a GF Value™ of €9.28 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 606 Healthcare Providers & Services companies, DocCheck AG ranks better than 63.7% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-22), DocCheck AG's share price is €11.60. DocCheck AG's Book Value per Share for the quarter that ended in Dec. 2025 was €8.20. Hence, DocCheck AG's PB Ratio of today is 1.41.
Good Sign:
DocCheck AG stock PB Ratio (=1.44) is close to 1-year low of 1.35.
The historical rank and industry rank for DocCheck AG's PB Ratio or its related term are showing as below:
FRA:AJ91'
s PB Ratio Range Over the Past 10 Years
Min: 0.97 Med: 2.06 Max: 5.79
Current: 1.45
During the past 13 years, DocCheck AG's highest PB Ratio was 5.79. The lowest was 0.97. And the median was 2.06.
FRA:AJ91's PB Ratio is ranked better than 63.7% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 2.005
vs FRA:AJ91: 1.45
During the past 12 months, DocCheck AG's average Book Value Per Share Growth Rate was 3.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of DocCheck AG was 21.10% per year. The lowest was 0.10% per year. And the median was 2.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
DocCheck AG PB Ratio Related Terms
DocCheck AG PB Ratio Historical Data
* Premium members only.
The historical data trend for DocCheck AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, DocCheck AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocCheck AG PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocCheck AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where DocCheck AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
DocCheck AG's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
DocCheck AG (FRA:AJ91) has a PB Ratio of 1.41 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DocCheck AG and its competitors. This is 32% below median its historical median of 2.06. Over the past decade, DocCheck AG's PB Ratio has ranged from 0.97 to 5.79. According to the industry distribution chart, DocCheck AG ranks #220 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 36.3%.
Is DocCheck AG's PB Ratio too high?
DocCheck AG's current PB Ratio of 1.41 is 32% below median its 10-year median of 2.06. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 5.79. The Healthcare Providers & Services industry median PB Ratio is 2.01. DocCheck AG's value of 1.41 is 29.7% below this industry median. Based on the distribution chart, DocCheck AG ranks #220 out of 606 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DocCheck AG has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DocCheck AG's PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DocCheck AG ranks #220 out of 606 companies for PB Ratio. This puts DocCheck AG in the upper half of its industry. The industry median PB Ratio is 2.01. DocCheck AG's value of 1.41 is 29.7% below this benchmark. Historically, DocCheck AG's own PB Ratio has ranged from 0.97 to 5.79 over the past decade. While the company's 10-year median is 2.06 vs. the industry median of 2.01, DocCheck AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 2.01, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocCheck AG's current PB Ratio of 1.41 is 29.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DocCheck AG and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocCheck AG's current PB Ratio is 1.41, which is 32% below median its own 10-year median of 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocCheck AG stock overvalued right now?
Based on GuruFocus' analysis, DocCheck AG (FRA:AJ91) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.28, compared to a current price of €11.60 — trading 25% above its estimated fair value. The current PB Ratio is 1.41, which is 32% below median its 10-year median of 2.06 and 29.7% below the Healthcare Providers & Services industry median of 2.01. DocCheck AG's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For DocCheck AG (FRA:AJ91), the current PB Ratio is 1.41 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocCheck AG (FRA:AJ91) Overvalued in 2026?
Based on GuruFocus' analysis, DocCheck AG stock appears to be overvalued.
The current stock price of €11.60 is trading 25% above its estimated GF Value™ of €9.28.
GuruFocus considers DocCheck AG to be Modestly Overvalued.
Key valuation signals for FRA:AJ91:
PB Ratio: 1.41 (32% below median its 10-year median of 2.06)
GF Value™: €9.28 vs. price of €11.60 (25% above fair value)
Industry Position: 29.7% below the Healthcare Providers & Services median (#220 of 606)
No single metric tells the full story. See the FRA:AJ91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocCheck AG is a Germany-based company engaged in the healthcare sector. It operates through subsidiaries: antwerpes AG develops integrated communication concepts for the healthcare sector, including social media and digital communication with focus on e-marketing concepts, search engine optimization (SEO), search engine advertising (SEA) and search engine marketing (SEM); DocCheck Medical Services GmbH operates an online platform for healthcare professionals, such as physicians and pharmacists; DocCheck Medizinbedarf und Logistik GmbH wholesales medical products from third parties and also produces own medical products, and DocCheck Guano AG is a venture capital company with focus on e-health companies and promotes healthcare startups.
71GF Score
Get the complete analysis for FRA:AJ91
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AJ91 has been successfully added to your 
